Plain-English translation of NCT04460352 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
The NEEDS trial is testing whether people with advanced esophageal cancer do equally well with two different treatment strategies. One approach uses chemotherapy, radiation, and then planned surgery to remove the esophagus. The other uses the same chemotherapy and radiation but skips the planned surgery — instead, doctors watch closely and only operate later if the cancer comes back or doesn't fully respond. The trial will track survival, quality of life, and eating ability to see which approach works best.
Currently, many patients with advanced esophageal cancer have surgery after chemotherapy and radiation, which is a major operation with significant recovery time. This trial asks whether some patients might do just as well — or even better — by avoiding surgery altogether and simply being monitored carefully, having surgery only if truly needed later. This could help spare many people from unnecessary major surgery while keeping them safe.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you will be randomly assigned to one of two groups. Both groups will receive chemotherapy (Carboplatin and Paclitaxel or similar drugs) combined with radiation therapy given five days a week over several weeks. After that, one group will have surgery to remove the esophagus within 8 weeks. The other group will have regular follow-up appointments and imaging scans to monitor for any cancer returning — and will only have surgery if the cancer doesn't fully respond or comes back. The trial will track you for at least one year after treatment, measuring your overall survival, ability to eat, and quality of life.
AI-generated summary from trial data · Jun 25, 2026 · Not medical advice
Canada
Ireland
Norway